Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Kuźma, Ł." wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Obesity – is it really so bad for a patient with coronary heart disease?
    Autorzy:
    Pogorzelski, S.
    Kuźma, Ł.
    Struniawski, K.
    Wróblewski, D.
    Gajewska_Bachórzewska, H.
    Dobrzycki, S.
    Powiązania:
    https://bibliotekanauki.pl/articles/1918824.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    Obesity
    body mass index
    acute coronary syndrome
    Opis:
    According to American Obesity Medicine Association obesity is a chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences. Obesity has been renowned as a risk factor of cardiovascular, endocrinological, orthopedic and many other diseases. But for the last two decades, there have been many reports of beneficial influence of overweight or obesity on patients with coronary heart disease. This phenomenon got a name of obesity paradox. It’s existence is a matter of lively discussion in medical world, and even if true, the protecting mechanisms of obesity need much deeper understanding.
    Źródło:
    Progress in Health Sciences; 2018, 8(2); 194-201
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Eptifibatide induced acute thrombocytopenia. Case report of 80- years old man with acute coronary syndrome
    Autorzy:
    Kuźma, Ł.
    Pogorzelski, S.
    Wróblewski, D.
    Struniawski, K.
    Róg-Makal, M.
    Nowak, K.
    Matys, U.
    Gajewska-Bachórzewska, H.
    Dobrzycki, S.
    Powiązania:
    https://bibliotekanauki.pl/articles/1918779.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    Thrombocytopenia
    glycoprotein IIb/ IIIa inhibitors
    acute coronary syndrome
    Opis:
    Introduction: Glycoprotein (Gp) IIb/IIIa is a platelet receptor participating in platelet aggregation. According to ESC guidelines, glycoprotein IIb/IIIa inhibitors might be considered during percutaneous coronary interventions in patients with the acute coronary syndrome. Purpose: A case study of profound thrombocytopenia in 80-year-old man with the acute coronary syndrome. Case presentation: An 80-year-old, medicationnaive man with acute coronary syndrome was admitted to the Department of Invasive Cardiology. Due to the unsuccessful invasive strategy, an intracoronary bolus of Gp IIb/IIIa inhibitor – eptifibatide - was administered. During the following intravenous infusion, large subcutaneous hematomas were observed. Eptifibatide infusion was discontinued. Drop in platelet count to 1 thou/μL without significant anemia was registered. A control sample in sodium citrate showed similarly low platelet count - 2 thou/uL. Acetylsalicylic acid and clopidogrel were discontinued, steroids were introduced. Neither PLT nor FFP transfusion were necessary. Consecutive lab tests showed the gradual increase of PLT up to 35 thou/μL at discharge. A week later, the patient did not complain of any cardiovascular or bleeding symptoms; hematomas resented significant involution. Laboratory findings were normal. During follow-up visit 30 days after the discharge, the patient presented no cardiovascular symptoms. Conclusions: There are patients at risk of druginduced thrombocytopenia, especially those with impaired kidney function and the elderly. In such cases, decisions concerning anti-platelet and antithrombotic therapy should be taken cautiously. Because of its rare occurrence, every case of severe thrombocytopenia in ACS patients should be reported. Moreover, such patients should be followed-up to minimalize risk of similar adverse events in the future.
    Źródło:
    Progress in Health Sciences; 2018, 8(2); 234-238
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies